ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT.
A live webcast will be available via the company’s investor website at www.oricpharma.com, and a replay will be accessible for 90 days after the event.
Details
News Market Reaction – ORIC
On Jan 7, the first trading day after this news, ORIC closed 6.63% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation time
- 9:45 a.m. PT
- Company overview on January 13, 2026
- Webcast replay period
- 90 days
- Replay of J.P. Morgan presentation available to investors
Historical Context
-
Phase 1b enozertinib EGFR exon 20 data with strong systemic and CNS activity.
-
Inducement stock options and RSUs granted to new non-executive employees.
-
Phase 1b enozertinib data in HER2 exon 20 NSCLC with 100% disease control rate.
-
Enozertinib showed high ORR and intracranial activity in EGFR atypical/PACC NSCLC.
-
Late-breaking oral presentations for enozertinib at ESMO Asia Congress 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
oncology medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:45 a.m. PT.
A live webcast of the company presentation will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor targeting EGFR exon 20 and atypical mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.